In Vivo Bioequivalence and In Vitro Similarity Factor (f2) for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match?
暂无分享,去创建一个
[1] J. Dressman,et al. Forecasting the Oral Absorption Behavior of Poorly Soluble Weak Bases Using Solubility and Dissolution Studies in Biorelevant Media , 2002, Pharmaceutical Research.
[2] Yi Tsong,et al. In Vitro Dissolution Profile Comparison—Statistics and Analysis of the Similarity Factor, f2 , 1998, Pharmaceutical Research.
[3] D P Vaughan,et al. Mathematical basis of point-area deconvolution method for determining in vivo input functions. , 1978, Journal of pharmaceutical sciences.
[4] Michael Levin. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .
[5] J. Devane,et al. Review of methodologies for the comparison of dissolution profile data. , 1997, Advances in experimental medicine and biology.
[6] F. Langenbucher. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel II. Distribution functions and moments. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[7] Filippos Kesisoglou,et al. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[8] J. W. Moore,et al. Mathematical comparison of dissolution profiles , 1996 .
[9] Jennifer B Dressman,et al. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[10] Jennifer B Dressman,et al. Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[11] Vinod P. Shah,et al. FDA Guidance for Industry 1 Extended Release Solid Oral Dosage forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations , 1997 .
[12] F. Langenbucher. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel: III. Convolution and deconvolution. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[13] J. Polli,et al. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. , 1997, Journal of pharmaceutical sciences.
[14] Michael Levin,et al. Supac-Mr: Modified Release Solid Oral Dosage Forms—Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation , 2001 .
[15] Christos Reppas,et al. Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration , 2001, Pharmaceutical Research.
[16] P. Costa,et al. Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.